
    
      Participants will receive ChimeriVax™-JE or diluent on Day 0 and diluent or ChimeriVax™-JE on
      Day 28. A subset of participants in each group will receive a booster dose of ChimeriVax™-JE
      at Month 6. Follow-up visits will occur at 12 and 24 months. Eligible participants will then
      enter the long-term immunogenicity follow-up period with visits at approximately 36, 48, and
      60 months after Day 0. No safety data will be collected in the long-term immunogenicity
      follow-up period.
    
  